Alkermes plc, of Dublin, reported that for the year ending Dec. 31, 2016, total revenues increased 19 percent, to $745.7 million, which included net sales of $209.0 million for Vivitrol (naltrexone for extended-release injectable suspension) and net sales of $47.2 million for the schizophrenia drug, Aristada (aripiprazole lauroxil).